Teva Pharmaceutical Industries Ltd (TEVA) Expected to Post Quarterly Sales of $4.27 Billion
Wall Street brokerages predict that Teva Pharmaceutical Industries Ltd (NYSE:TEVA) will post $4.27 billion in sales for the current quarter, Zacks Investment Research reports. Seven analysts have provided estimates for Teva Pharmaceutical Industries’ earnings. The lowest sales estimate is $4.20 billion and the highest is $4.32 billion. Teva Pharmaceutical Industries posted sales of $4.70 billion in the same quarter last year, which would indicate a negative year over year growth rate of 9.1%. The company is scheduled to issue its next quarterly earnings report on Thursday, August 1st.
According to Zacks, analysts expect that Teva Pharmaceutical Industries will report full-year sales of $17.18 billion for the current financial year, with estimates ranging from $17.06 billion to $17.43 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $17.13 billion, with estimates ranging from $16.73 billion to $17.76 billion. Zacks’ sales averages are an average based on a survey of analysts that follow Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.55 by $0.02. Teva Pharmaceutical Industries had a positive return on equity of 16.84% and a negative net margin of 18.66%. The firm had revenue of $4.30 billion for the quarter, compared to the consensus estimate of $4.38 billion. The business’s revenue for the quarter was down 15.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.94 EPS.
In other Teva Pharmaceutical Industries news, VP Richard Daniell sold 2,098 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $16.88, for a total transaction of $35,414.24. Following the completion of the transaction, the vice president now owns 2,098 shares in the company, valued at approximately $35,414.24. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Deborah A. Griffin sold 4,107 shares of the stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $16.88, for a total value of $69,326.16. Following the transaction, the insider now owns 2,941 shares of the company’s stock, valued at approximately $49,644.08. The disclosure for this sale can be found here. In the last quarter, insiders have sold 11,650 shares of company stock valued at $193,325. Corporate insiders own 0.49% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the business. Northstar Group Inc. grew its holdings in shares of Teva Pharmaceutical Industries by 34.9% in the 4th quarter. Northstar Group Inc. now owns 15,468 shares of the company’s stock valued at $239,000 after acquiring an additional 4,000 shares in the last quarter. State Board of Administration of Florida Retirement System lifted its stake in Teva Pharmaceutical Industries by 3.5% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 49,181 shares of the company’s stock valued at $758,000 after purchasing an additional 1,681 shares during the last quarter. AGF Investments America Inc. lifted its stake in Teva Pharmaceutical Industries by 2.5% in the 4th quarter. AGF Investments America Inc. now owns 60,321 shares of the company’s stock valued at $930,000 after purchasing an additional 1,458 shares during the last quarter. Bank of Montreal Can lifted its stake in Teva Pharmaceutical Industries by 7.3% in the 1st quarter. Bank of Montreal Can now owns 570,059 shares of the company’s stock valued at $8,938,000 after purchasing an additional 38,659 shares during the last quarter. Finally, Boston Advisors LLC lifted its stake in Teva Pharmaceutical Industries by 18.0% in the 4th quarter. Boston Advisors LLC now owns 23,555 shares of the company’s stock valued at $363,000 after purchasing an additional 3,592 shares during the last quarter. Hedge funds and other institutional investors own 67.00% of the company’s stock.
Shares of TEVA stock traded down $0.66 during trading hours on Wednesday, reaching $11.44. The company had a trading volume of 46,912,084 shares, compared to its average volume of 11,558,154. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66. The company has a market cap of $12.44 billion, a P/E ratio of 4.09, a price-to-earnings-growth ratio of 1.54 and a beta of 1.30. Teva Pharmaceutical Industries has a 1-year low of $11.26 and a 1-year high of $25.96.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.